Elske G.
- Country
- The Netherlands
- Department
- Medical Oncology
Research Overview
- Randomized Controlled Trial of Induction Chemotherapy with Irinotecan, Folinic Acid, and Oxaliplatin Followed by Chemoradiotherapy for Locally Recurrent Rectal Cancer
- Phase 2 Randomized Study of Liposomal Irinotecan, Carboplatin, and Oxaliplatin in First-Line Treatment of Metastatic or Locally Advanced Esophagogastric Cancer
Data & Insights
Has run more than one trial at 11 of 54 partner sites.
Specializations
Colorectal Cancer Research
This investigator specializes in advanced therapeutic approaches for colorectal cancer, with particular focus on KRAS G12C mutations and innovative combination therapies. Their research extends to colorectal liver metastases treatment strategies.
- Advanced mutation-specific treatments
- Metastatic disease management
- Hepatic arterial infusion therapy
The investigator works with novel therapeutic combinations including targeted therapies and immunotherapy approaches.
Pancreatic Cancer Studies
The investigator conducts research in pancreatic ductal adenocarcinoma, exploring innovative treatment combinations that include immunotherapy and personalized therapeutic approaches.
- Adjuvant therapy development
- Combination treatment strategies
- Post-surgical therapeutic interventions
Their work focuses on improving survival outcomes through combined therapeutic modalities.
Precision Oncology
The investigator specializes in biomarker-driven therapies, particularly focusing on dMMR/MSI-H status in colon cancer and personalized treatment approaches.
- Perioperative immunotherapy
- Molecular profiling applications
- Stage-specific treatment strategies
Their research encompasses targeted therapeutic interventions based on specific molecular characteristics.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.